LifeVantage (LFVN) 17th Annual LD Micro Main Event Conference summary

Business overview and market position

• Achieved profitability of just under $0.60 per share last year, with a strong balance sheet and 70% of revenue from subscriptions.

• Operates in the direct selling channel, with 150,000 consultants and 125,000 customers across 20 countries.

• 78% of revenue is from North America, with significant growth opportunities identified in Asia and other international markets.

• Focuses on wellness and personal care products, differentiating through cellular activation science.

Product innovation and clinical results

• Flagship product Protandim Nrf2 accounts for over 50% of revenue and is clinically proven to reduce oxidative stress by 40% in 30 days.

• Launched a liquid collagen product two years ago, shown to double collagen production and density.

• Recently introduced a GLP-1 system for weight management, clinically proven to increase GLP-1 by 140%, reduce visceral fat by 27%, and overall fat by 4% with no muscle loss.

• GLP-1 product reduces food cravings and supports long-term lifestyle changes, with 95% of users reporting decreased sugar cravings.

Market reception and growth strategy

• October marked the highest booking month in company history, with new enrollments quadrupling the monthly average.

• Sold out of the new GLP-1 product, with backorders expected to clear by mid-December.

• Plans to launch the GLP-1 product internationally in March-April next year.

• Emphasizes product stacking for both scientific and financial benefits, increasing multi-product revenue share.